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FOURTEEN kilodalton phospholipase A molecules (PLA2)
are classified into two groups, I- and II-PLA2, and only the
latter has been considered to play a pathogenetic role in
various forms oftissue inflammation. Previouslywe dem-
onstrated high PLA activity in gingival crevicular fluid
(GCF) of patients with periodontal disease, without deter-
mining the group of the enzyme involved. In this study,
the activity, groups and levels ofenzyme in gingiva taken
from 13 sites of periodontal disease were determined
using both biochemical and radioimmunological meth-
ods. A linear correlation between the activity and the
level of II-PLA was observed. No I-PLA was found in any
of the samples tested. These data suggest that the PLA
activity found in the GCF of patients with periodontal
disease does not belong to the I-PLA but to the II-PLA
group.
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Introduction
Intracellular phospholipase A (PEa2; EC 3.1.1.4)
catalyses the hydrolysis of the ester bound at the sn-
2 position of glycerophospholipids and is a key
enzyme in the production of potent inflammatory
mediators, including prostaglandins, leukotrienes
and platelet activating factor. Recently, it has been
demonstrated that mammalian PEA can be classified
into at least three groups on the basis of their primary
structure. Two of these groups are designated I- and
II-PLA2, and are found in pancreatic juice and a
variety of tissues other than pancreas, respectively.
Both groups have a molecular mass of 14 kDa. The
third group is present in the cytosolic fraction of
various tissues and has a molecular weight of 85
kDa. Among these enzyme groups, only II-PLA has
been considered to play an important role in the
process of inflammation, for example, in rheumatoid
arthritis or inflammatory bowel disease. In our
previous studies, it was demonstrated that rat
gingival cells had II-PLA activity and that this activity
was induced by the inflammatory cytokines
interleukin-l]3 (IL-113) and tumour necrosis factor-cz
(TNF-00, but inhibited by the anti-inflammatory
cytokine transforming-growth factor-]3 (TGF-[). 6,7 In
addition, we also demonstrated PLA activity in hu-
man gingival crevicular fluid (GCF) from patients
with periodontal disease and indicated that this ac-
tivity appeared to reflect periodontal disease condi-
tions (active or resting), suggesting that its potential
usefulness as a marker for the assessment of disease
activity. However, the maximum volume ofGCF was
too small to determine whether the activity if con-
tained belonged to the II-PLA2 group, even with the
sensitive method we employed. Since GCF contains
infiltrates from adjacent gingival tissue that enter the
gingival crevice, the enzyme activity in GCF reflects
that in the gingival tissue.
To clarify the type of PEa present in GCF from
patients with periodontal disease, the activity and
level of PEA were measured in the gingival tissue
using both biochemical and radioimmunological as-
say systems, respectively.
Materials and Methods
Gingival tissue: Gingival tissues from seven patients
(mean age 42.0 + 2.2 years) who had at least five
teeth with a pocket depth of more than 6 mm were
used. The depth of the periodontal pocket (gingival
crevice), which usually indicates the degree of peri-
odontal tissue destruction, and its measurement is
considered to be the most reliable tool for the diag-
nosis and assessment of periodontal disease. A tooth
with healthy periodontal tissue has a pocket depth of
less than 2 mm, whereas a tooth with a periodontal
pocket depth of more than 4 mm is considered to be
affected by periodontal disease. None of the patients
were receiving or had previously received any medi-
cation or periodontal treatment before the study.
Gingival tissue preparation: Inflammatory gingival
tissues were taken from 13 sites in the seven patients
at the time of periodontal surgical therapy. The
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excised tissues were rinsed thoroughly with ice-cold
isotonic solution and weighed. Then they were
minced and homogenized in 100 mM Tris-HCl (pH
7.4) using a glass homogenizer at 2 000 rpm for 30 s,
followed by centrifugation at 20 000 x g. An aliquot
of each supernatant was used as the enzyme source
for either biochemical determination of PLA2 activity
or radioimmunological PEA assay.
Biochemical assayfor PLAe activity: Phospholipase
A activity was determined according to the method
described by Tojo et al. using 0.8 mM 1-palmitoyl-
2 oleoyl-sn-glycero-3-phosphoglycerol as a substrate
in the presence of 5 mM cholate. Fatty acids released
by PLA were labelled with 9-anthryldiazomethane
and then separated by high-performance liquid chro-
matography column, followed by quantitation using
marganic acid as an internal standard. Calcium-de-
pendent PEt was estimated as the difference be-
tween the activity assayed in the presence of 5 mM
CaCL and that in the presence of 10 mM
ethylenediaminetetraacetate.
RadioimmunoassayforI-and II-PLA2: The level of I-
and II-PEt in the supernatant was measured using
a radioimmunoassay kit (Shionogi Pharmaceutical
Ltd, Osaka, Japan) and a monoclonal antibody
against human pancreatic group I- or splenic II-PLA
as described elsewhere.1
Results and Discussion
Figure 1 shows the sensitivity of the RIA used in
this study and representative II-PLA levels as a func-
tion of wet weight of gingival tissue. As can be seen,
a minimum gingival tissue wet weight of about 1 mg
was enough for detection of II-PLA2. The level of II-
PLA increased with gingival wet weight over a range
of I to 25 mg in a dose-dependent manner. It was not
possible to determine whether the activity belonged
to I- or II-PEt in GCF, because usually the volume
of GCF is less than 3 ILtl, which is insufficient for RIA.
However, the results suggested that the PLA2 activity
detected in GCF was classifiable by examining bi-
opsy samples of gingival tissue. It would be accept-
able and meaningful not only for periodontologists
but also for patients for about 1 mg wet weight of
gingiva to be taken as a biopsy sample to obtain
precise and predictable information on the diseased
sites.
Table 1 shows the levels of PEA determined by the
RIA in each supernatant of gingival tissue from 13
different sites. The mean level of II-PLA was 83.7 pg/
mg wet weight, with wide ranges in the enzyme level
from 5 to 216 pg/mg wet weight. This wide range of
values was not surprising, because our previous data
showed that PLA activity was well correlated only
with periodontal disease activity, and not with the
degree of destruction caused by the previous disease
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FIG. 1. Levels of group I- and II-phospholipase A (PLA2) as a function of
wet weight of gingival tissue. Gingival tissue from a patient with periodontal
disease was taken at the time of surgical therapy. The level of II-PLA
increased with the increase of tissue weight, but no I-PLA was found.
activity. It has also been shown that II-PLA2 activities
found in inflamed sites other than those due to
periodontitis, such as rheumatoid arthritis, Crohn’s
disease and septic shock,
11 are well correlated with
disease activity, and thus II-PLA2 is believed to play
an important role in the initiation and propagation of
the inflammatory process in these diseases. Recently,
we showed that GCF sampled from sites of active
periodontitis had higher PEA activity than those
from quiescent sites, although we could not identify
whether the activity belonged to group or II. These
activities detected in GCF were thought to be those
induced in the inflamed gingival tissues followed by
secretion into the gingival crevice. In contrast, none
of the samples tested had any detectable levels of I-
Table 1. The levels of I-PLA and II-PLA
Site PLA (pg/mg wet weight)
Group Group II
n.d. 12
2 n.d. 169
3 n.d. 120
4 n.d. 88
5 n.d. 5
6 n.d. 206
7 n.d. 216
8 n.d. 131
9 n.d. 6
10 n.d. 14
11 n.d. 87
12 n.d. 17
13 n.d. 17
Levels of I-PLA2 and II-PLA2 were determined by RIA. A
wide range of II-PLA levels was observed in gingival
tissues, but no I-PLA2 was found in any of the samples
tested, n.d., not detectable.
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FIG. 2. Relationship between the activity and level of II-PLA There is a
linear correlation between II-PLA2 activity and level (r 0.907, Pearson
product moment correlation coefficients).
PLA using this assay system. These results suggest
that the PLA2 activity found in the GCF of patients
with periodontal disease is not I-PLA but II-PLA2.
It has been reported that serum contains many
factors that modulate the activity of PEA2, for exam-
ple, an activating protein such as PLA2-activating
protein
12 and an inhibitory protein such as C3dg. 13 Up
to now it has not been clarified whether the elevated
PEA2 activity in GCF and gingival tissue is due to an
increase in enzyme concentration or to direct activa-
tion of the enzyme. Figure 2 shows the relationship
between the level of II-PLAz determined by RIA and
the activity determined by biochemical assay in the
13 samples. As can be seen, a highly significant
correlation (r 0.907, p < 0.001) between the level
and activity of II-PLA2 was observed. These findings
indicate that the PLA2 activity detected in GCF was
attributable primarily to an increase in the protein
concentration of II-PLA2, probably via de novo pro-
tein synthesis in the gingiva, and not to activation of
the enzyme. This close correlation between the level
and activity of II-PLA agrees well with previous
reports on septic shock,
11 malaria,
14 or Crohn’s dis-
ease and ulcerative colitis. 15
We showed that inflammatory cytokines such as
IL-1l] and TNF-{x induced, whereas an anti-inflamma-
tory cytokine, TFG-{], inhibited the synthesis and
secretion of II-PLA2 in cultured rat gingival
fibroblastic cells. 6,7 It is well known that these
cytokines are present in GCF and levels of IL-I in
gingival tissue correlate well with disease activity of
periodontitis.
16 Although it was not possible to iden-
tify the source of II-PLA2 in gingival tissue from this
study, it is considered that gingival cells in the in-
flamed sites are one of the most likely candidates.
In summary, the present results suggest that PLA
activity detected in GCF does not belong to I-PLA2,
but to II-PLA2. It is also suggested that measurement
of either the level of II-PLA in biopsy samples of
inflamed gingiva or the enzyme activity in GCF may
be useful for detecting sites of active disease in
periodontitis.
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